These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. The handling of metastatic colorectal cancer. Fornarini G; Guglielmi A; Sobrero A Ann Oncol; 2005; 16 Suppl 2():ii141-3. PubMed ID: 15958445 [No Abstract] [Full Text] [Related]
9. Targeting Secondary and Tertiary Resistance to BRAF Inhibition in BRAF V600E-Mutated Metastatic Colorectal Cancer. Akhoundova D; Pietge H; Hussung S; Kiessling M; Britschgi C; Zoche M; Rechsteiner M; Weber A; Fritsch RM JCO Precis Oncol; 2021 Nov; 5():1082-1087. PubMed ID: 34994629 [No Abstract] [Full Text] [Related]
10. Emerging phase 3 data in relapsed/refractory metastatic colorectal cancer. Goldberg R Clin Adv Hematol Oncol; 2016 Jan; 14(1):30-3. PubMed ID: 27057664 [No Abstract] [Full Text] [Related]
11. Third-line treatment and beyond in metastatic colorectal cancer: What do we have and what can we expect? Ayala-de Miguel C; Jiménez-Castro J; Sánchez-Vegas A; Díaz-López S; Chaves-Conde M Crit Rev Oncol Hematol; 2024 Oct; 202():104454. PubMed ID: 39043356 [TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of biweekly cetuximab plus chemotherapy in first-line treatment for RAS wild-type metastatic colorectal cancer. Giuliani J J Oncol Pharm Pract; 2022 Oct; 28(7):1674-1676. PubMed ID: 35833215 [No Abstract] [Full Text] [Related]
13. Why precision medicine should be applied across the continuum of care for metastatic colorectal cancer patients. Puzzoni M; Ziranu P; Demurtas L; Lai E; Mariani S; Liscia N; Soro P; Pretta A; Impera V; Camera S; Musio F; Persano M; Donisi C; Tolu S; Balconi F; Scartozzi M Future Oncol; 2020 Jan; 16(2):4337-4339. PubMed ID: 31793396 [No Abstract] [Full Text] [Related]
14. BRAF mutation in metastatic colorectal cancer. Tol J; Nagtegaal ID; Punt CJ N Engl J Med; 2009 Jul; 361(1):98-9. PubMed ID: 19571295 [No Abstract] [Full Text] [Related]
15. Options for patients with metastatic colorectal cancer who progress after second-line therapy. Marshall JL Clin Adv Hematol Oncol; 2019 Mar; 17 Suppl 7(3):2-4. PubMed ID: 31730589 [No Abstract] [Full Text] [Related]
16. Chemotherapy and immunotherapy in metastatic colorectal cancer. Copur MS; Norvell M; Obermiller A N Engl J Med; 2009 May; 360(20):2135; author reply 2135-6. PubMed ID: 19445033 [No Abstract] [Full Text] [Related]
18. Trastuzumab deruxtecan in HER2-positive metastatic colorectal cancer: less is more? Roodhart JML; Koopman M Lancet Oncol; 2024 Sep; 25(9):1104-1105. PubMed ID: 39116901 [No Abstract] [Full Text] [Related]
19. Recent advances in the treatment of metastatic colorectal cancer in Taiwan. Lin YL; Yeh KH; Cheng AL J Formos Med Assoc; 2011 Jan; 110(1):1-3. PubMed ID: 21316006 [No Abstract] [Full Text] [Related]